"On 4 February 2015, the Company released a Notice for an...

"On 4 February 2015, the Company released a Notice for an Extraordinary General Meeting of shareholders that is to
be held at 10.00 am on Friday, 6 March 2015, at the Company’s offices.  Shareholders will be asked to consider and, if
thought fit, to pass the following resolutions:

Resolution 1 – Ratification of prior Placement of Shares to Ironridge Global IV Ltd
Resolution 2 – Ratification of prior Placement of Shares to Kentgrove Capital Growth Fund
Resolution 3 – Approval of Standby Equity Placement Facility (Kentgrove Capital Growth Fund)
Resolution 4 - Approval of proposed new placement of Shares to sophisticated investors

Under the Agreement, Kentgrove Capital may provide the Company with up to A$24 million of equity capital via
placements over the next 24 months. Proceeds from the Facility will be used to fund the growth of the Company’s
flagship lead breast cancer risk test, BREVAGenplus and for general working capital. "

So who is Kentgrove Capital?

The Kentgrove Capital Fund is an absolute return fund with an objective of generating strong returns for investors over the medium and long term. The Fund will generally hold a concentrated portfolio of equities based on bottom-up stock selection. Our primary investment strategy is to conduct fundamental research on Australian stocks and buy when we consider a stock to be significantly undervalued, allowing ample margin of safety.

http://kentgrovecapital.com.au/about/